HRP20190219T1 - Spojevi za tretman pretilosti i postupci za njihovu uporabu - Google Patents

Spojevi za tretman pretilosti i postupci za njihovu uporabu

Info

Publication number
HRP20190219T1
HRP20190219T1 HRP20190219TT HRP20190219T HRP20190219T1 HR P20190219 T1 HRP20190219 T1 HR P20190219T1 HR P20190219T T HRP20190219T T HR P20190219TT HR P20190219 T HRP20190219 T HR P20190219T HR P20190219 T1 HRP20190219 T1 HR P20190219T1
Authority
HR
Croatia
Prior art keywords
obesity
compounds
treatment
methods
Prior art date
Application number
HRP20190219TT
Other languages
English (en)
Inventor
Umut Ozcan
Original Assignee
The Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children's Medical Center Corporation filed Critical The Children's Medical Center Corporation
Publication of HRP20190219T1 publication Critical patent/HRP20190219T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
HRP20190219TT 2013-11-26 2019-02-01 Spojevi za tretman pretilosti i postupci za njihovu uporabu HRP20190219T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908998P 2013-11-26 2013-11-26
PCT/US2014/067393 WO2015081093A1 (en) 2013-11-26 2014-11-25 Compounds for the treatment of obesity and methods of use thereof
EP14816018.7A EP3074033B1 (en) 2013-11-26 2014-11-25 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20190219T1 true HRP20190219T1 (hr) 2019-03-22

Family

ID=52134396

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190219TT HRP20190219T1 (hr) 2013-11-26 2019-02-01 Spojevi za tretman pretilosti i postupci za njihovu uporabu

Country Status (17)

Country Link
US (1) US20160375039A1 (hr)
EP (1) EP3074033B1 (hr)
JP (2) JP6672157B2 (hr)
AU (2) AU2014354831B2 (hr)
CA (1) CA2931826C (hr)
CY (1) CY1122551T1 (hr)
DK (1) DK3074033T3 (hr)
ES (1) ES2709976T3 (hr)
HR (1) HRP20190219T1 (hr)
HU (1) HUE042196T2 (hr)
LT (1) LT3074033T (hr)
PL (1) PL3074033T3 (hr)
PT (1) PT3074033T (hr)
RS (1) RS58422B1 (hr)
SI (1) SI3074033T1 (hr)
TR (1) TR201901299T4 (hr)
WO (1) WO2015081093A1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153933A1 (en) * 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN106008657B (zh) * 2016-05-20 2017-11-21 天津中医药大学 苦蘵苦素i及提取方法及用途
IT201800005336A1 (it) * 2018-05-14 2019-11-14 Composizioni per uso nel trattamento dell’obesità
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
CN113599502A (zh) * 2021-07-22 2021-11-05 廖儒佳 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU531759B2 (en) 1978-04-17 1983-09-08 Ici Ltd. Electrostatic spraying
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
EP0832220A1 (en) 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
KR19990028388A (ko) 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법
ES2216055T3 (es) 1995-08-17 2004-10-16 Amgen Inc Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
ES2217327T3 (es) 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
CA2258504A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
CA2263826A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
JP2001500869A (ja) 1996-09-20 2001-01-23 ヘキスト、アクチェンゲゼルシャフト 第ｉｉ種糖尿病におけるインスリン耐性を治療するためのレプチンアンタゴニストの使用
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
HU227088B1 (en) 1996-12-20 2010-06-28 Amgen Inc Ob fusion protein compositions and process for producing thereof
JP4086908B2 (ja) 1997-04-17 2008-05-14 アムジエン・インコーポレーテツド 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法
CA2293504A1 (en) 1997-06-06 1998-12-10 Valur Emilsson Use of leptin antagonists for the treatment of diabetes
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
WO2000009165A1 (en) 1998-08-10 2000-02-24 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
WO2000020872A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1151102B1 (en) 1999-02-12 2006-04-19 Amgen Inc. Glycosylated leptin compositions and related methods
ES2418954T3 (es) 2001-10-22 2013-08-19 Amgen, Inc. Uso de la leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
CN101500611A (zh) * 2006-06-23 2009-08-05 埃斯蒂维实验室股份有限公司 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
WO2012106393A2 (en) * 2011-02-01 2012-08-09 University Of Kansas Withanolide isolated from physalis longifolia and analogs and methods of use thereof

Also Published As

Publication number Publication date
SI3074033T1 (sl) 2019-03-29
EP3074033A1 (en) 2016-10-05
DK3074033T3 (en) 2019-02-11
CY1122551T1 (el) 2021-01-27
CA2931826C (en) 2021-11-16
AU2014354831A1 (en) 2016-06-09
JP2020059744A (ja) 2020-04-16
ES2709976T3 (es) 2019-04-22
RS58422B1 (sr) 2019-04-30
JP2016537431A (ja) 2016-12-01
AU2018200517A1 (en) 2018-02-15
JP6672157B2 (ja) 2020-03-25
PL3074033T3 (pl) 2019-08-30
CA2931826A1 (en) 2015-06-04
US20160375039A1 (en) 2016-12-29
HUE042196T2 (hu) 2019-06-28
WO2015081093A1 (en) 2015-06-04
TR201901299T4 (tr) 2019-02-21
LT3074033T (lt) 2019-02-25
AU2018200517B2 (en) 2019-12-19
AU2014354831B2 (en) 2017-10-26
PT3074033T (pt) 2019-02-08
EP3074033B1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
IL243976A0 (en) kdm1a inhibitors for disease treatment
HK1221408A1 (zh) 用於治療成膠質細胞瘤的組合療法
HK1254296A1 (zh) 治療性化合物和其用途
HK1251494A1 (zh) 治療癌症的方法和組合物
GB201320729D0 (en) Therapeutic compounds and their use
EP2970317A4 (en) PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
PT3021838T (pt) Tratamento para a obesidade
EP2968298A4 (en) 2,4-THIAZOLIDINEDIONES ENRICHED IN DEUTERIUM AND METHODS OF TREATMENT
HK1217092A1 (zh) 治療性化合物及其用途
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
GB201309375D0 (en) Medical methods and compounds for medical use
GB201311361D0 (en) Compounds and their therapeutic use
GB201308736D0 (en) Compounds and their therapeutic use
GB201308665D0 (en) Device for the treatment of bone conditions
AU2013900139A0 (en) Device for the treatment of snoring
GB201309379D0 (en) Medical methods and compounds for medical use
GB201309376D0 (en) Medical methods and compounds for medical use
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use